Pub Date : 2025-10-14DOI: 10.1186/s41927-025-00571-2
Melissa Sipley, Saania N Zafar, Manuel Ester, Glen Hazlewood, Kiran Dhiman, Alexandra Charlton, Karen L Then, Erika Dempsey, Richard Lester, Alison M Hoens, Diane Lacaille, Sarah Sloss, Cheryl Barnabe, Dianne Mosher, Claire E H Barber
Objective: Text-based messaging support can improve rheumatoid arthritis (RA) care delivery by connecting patients with healthcare providers (HCPs) in an efficient and convenient manner. However, the nature and appropriateness of patient messaging in this new care model are unknown. The aim of this study was to (1) analyze the frequency and nature of text messages patients sent to their HCPs, and (2) to identify patient characteristics associated with higher texting frequency in a pilot of a text-based messaging (using the WelTel platform) added to usual rheumatology care.
Methods: Seventy patients with RA participated in a 6-month pilot. Automated "How are you?" texts were sent monthly, and patients were encouraged to respond according to their current situation. Qualitative content analysis was conducted to thematically categorize and quantify common words and phrases. Regression analysis was conducted to determine if a relationship existed between the number of text messages and age, sex, care complexity (using a validated instrument), number of medications, and burden of comorbidities.
Results: A total of 1404 text messages were sent by patients, with 257 messages requiring a response. Three main themes for texting topics emerged: RA symptom reporting, medication management, and COVID-19 questions. Patients with higher care complexity had a higher frequency of texting (p = 0.025); however, no association was observed with other patient characteristics.
Conclusion: Patients with higher complexity texted HCPs more frequently. Messages were highly aligned with patient care needs. Future directions should include assessing the impact of text messaging-enhanced care on patient outcomes and overall healthcare utilization.
{"title":"Text-based messaging to support rheumatoid arthritis care: an analysis of frequency and content of text-messages.","authors":"Melissa Sipley, Saania N Zafar, Manuel Ester, Glen Hazlewood, Kiran Dhiman, Alexandra Charlton, Karen L Then, Erika Dempsey, Richard Lester, Alison M Hoens, Diane Lacaille, Sarah Sloss, Cheryl Barnabe, Dianne Mosher, Claire E H Barber","doi":"10.1186/s41927-025-00571-2","DOIUrl":"10.1186/s41927-025-00571-2","url":null,"abstract":"<p><strong>Objective: </strong>Text-based messaging support can improve rheumatoid arthritis (RA) care delivery by connecting patients with healthcare providers (HCPs) in an efficient and convenient manner. However, the nature and appropriateness of patient messaging in this new care model are unknown. The aim of this study was to (1) analyze the frequency and nature of text messages patients sent to their HCPs, and (2) to identify patient characteristics associated with higher texting frequency in a pilot of a text-based messaging (using the WelTel platform) added to usual rheumatology care.</p><p><strong>Methods: </strong>Seventy patients with RA participated in a 6-month pilot. Automated \"How are you?\" texts were sent monthly, and patients were encouraged to respond according to their current situation. Qualitative content analysis was conducted to thematically categorize and quantify common words and phrases. Regression analysis was conducted to determine if a relationship existed between the number of text messages and age, sex, care complexity (using a validated instrument), number of medications, and burden of comorbidities.</p><p><strong>Results: </strong>A total of 1404 text messages were sent by patients, with 257 messages requiring a response. Three main themes for texting topics emerged: RA symptom reporting, medication management, and COVID-19 questions. Patients with higher care complexity had a higher frequency of texting (p = 0.025); however, no association was observed with other patient characteristics.</p><p><strong>Conclusion: </strong>Patients with higher complexity texted HCPs more frequently. Messages were highly aligned with patient care needs. Future directions should include assessing the impact of text messaging-enhanced care on patient outcomes and overall healthcare utilization.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"119"},"PeriodicalIF":2.5,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12523196/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145291060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-13DOI: 10.1186/s41927-025-00578-9
Khaled A A Abdelgalil, Nihal Fathi, Fatma H El Nouby, Nour A Mohammed, Loay I Aglan
{"title":"Correction: Associations of PTPN22 and PADI4 polymorphisms with rheumatoid arthritis in ASWAN.","authors":"Khaled A A Abdelgalil, Nihal Fathi, Fatma H El Nouby, Nour A Mohammed, Loay I Aglan","doi":"10.1186/s41927-025-00578-9","DOIUrl":"10.1186/s41927-025-00578-9","url":null,"abstract":"","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"117"},"PeriodicalIF":2.5,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12516867/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145285551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<p><strong>Background: </strong>Rheumatoid arthritis (RA) is a chronic autoimmune disorder that increases the risk of systemic complications, particularly metabolic syndrome (MetS). MetS, defined by central obesity, hypertension, hyperglycemia, and dyslipidemia, not only raises cardiovascular risk but also worsens the prognosis of RA. This meta-analysis aimed to estimate the global prevalence of MetS in RA patients and identify clinical factors contributing to its occurrence.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted in PubMed, Scopus, and Web of Science. Studies included in the analysis diagnosed RA and defined MetS using standardized guidelines. Pooled estimates were calculated using a random-effects model. Heterogeneity was assessed using the I² statistic. All statistical analyses were conducted using Stata. The study is registered with PROSPERO (CRD420251007337).</p><p><strong>Results: </strong>The overall pooled prevalence of MetS among RA patients was 30.3% (95% CI: 28.5-32.2). Country-specific analyses showed the highest prevalence in Iraq (57.3%; 95% CI: 49.7-66.4), Croatia (49.6%; 95% CI: 35.8-63.3), and Singapore (47.1%; 95% CI: 42.7-51.6), and the lowest in Congo (12.0%; 95% CI: 5.5-20.5), Algeria (14.0%; 95% CI: 10.0-18.7), and South Korea (17.2%; 95% CI: 7.3-30.1). When stratified by continent, the estimates varied noticeably. In Africa, the proportion was 25.7% (95% CI: 21.6-30.0%); in Asia, the estimate rose to 30.8% (95% CI: 27.1-34.6%); Europe recorded a similar figure at 29.8% (95% CI: 26.9-32.7%); North America had an estimate of 31.1% (95% CI: 25.5-36.9%); and South America demonstrated the highest proportion at 38.8% (95% CI: 34.4-43.3%). Meta-regression analyses identified significant associations between MetS prevalence and key clinical variables, including waist circumference (WC) (β = 0.01; P = 0.01), body mass index (BMI) (β = 0.04; P < 0.01), triglycerides (TG) (β < 0.01; P = 0.04), and fasting blood glucose (FBG) (β < 0.01; P < 0.01), with high-density lipoprotein (HDL) levels showing an inverse association (β = -0.01; P < 0.01). Among various diagnostic criteria, the highest prevalence estimates were obtained with the National Cholesterol Education Program and International Diabetes Federation (NCEP/IDF) criteria (39.2%; 95% CI: 30.6-48.1), followed by the Joint Consensus (JC) criteria (37.2%; 95% CI: 28.0-46.9) and the 2004 revision of the National Cholesterol Education Program ATP III (NCEP 2004) criteria (35.4%; 95% CI: 29.0-42.0).</p><p><strong>Conclusion: </strong>The substantial prevalence of MetS among RA patients underscores the need for a proactive, integrated approach to cardiovascular risk management. Clinicians should consider routine screening for MetS components-such as central obesity, hypertension, dysglycemia, and dyslipidemia-particularly given the significant associations with WC, BMI, TG, and FBG levels.</p><p><strong>Clinical trial number: </strong>Not applica
{"title":"Global prevalence of metabolic syndrome in patients with Rheumatoid arthritis: a systematic review and meta-analysis.","authors":"Maryam Jafari, Kishan Patel, Abinash Mahapatro, Bita Amirian, Casra Saeedi, Satabdi Sahu, Mohit Mirchandani, Herby Jeanty, Elan Mohanty, Nakka Raghuma, Saisree Reddy Adla Jala, Shika M Jain, Pavan Devulapally, Rahman Hameed Mohammed Abdul, Pegah Rashidian, Negin Letafatkar, Farahnaz Joukar, Forough Heidarzad, Mohammad-Javad Khosousi, Mohammad Amin Karimi, Seyyed Mohammad Hashemi, Ehsan Amini-Salehi","doi":"10.1186/s41927-025-00572-1","DOIUrl":"10.1186/s41927-025-00572-1","url":null,"abstract":"<p><strong>Background: </strong>Rheumatoid arthritis (RA) is a chronic autoimmune disorder that increases the risk of systemic complications, particularly metabolic syndrome (MetS). MetS, defined by central obesity, hypertension, hyperglycemia, and dyslipidemia, not only raises cardiovascular risk but also worsens the prognosis of RA. This meta-analysis aimed to estimate the global prevalence of MetS in RA patients and identify clinical factors contributing to its occurrence.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted in PubMed, Scopus, and Web of Science. Studies included in the analysis diagnosed RA and defined MetS using standardized guidelines. Pooled estimates were calculated using a random-effects model. Heterogeneity was assessed using the I² statistic. All statistical analyses were conducted using Stata. The study is registered with PROSPERO (CRD420251007337).</p><p><strong>Results: </strong>The overall pooled prevalence of MetS among RA patients was 30.3% (95% CI: 28.5-32.2). Country-specific analyses showed the highest prevalence in Iraq (57.3%; 95% CI: 49.7-66.4), Croatia (49.6%; 95% CI: 35.8-63.3), and Singapore (47.1%; 95% CI: 42.7-51.6), and the lowest in Congo (12.0%; 95% CI: 5.5-20.5), Algeria (14.0%; 95% CI: 10.0-18.7), and South Korea (17.2%; 95% CI: 7.3-30.1). When stratified by continent, the estimates varied noticeably. In Africa, the proportion was 25.7% (95% CI: 21.6-30.0%); in Asia, the estimate rose to 30.8% (95% CI: 27.1-34.6%); Europe recorded a similar figure at 29.8% (95% CI: 26.9-32.7%); North America had an estimate of 31.1% (95% CI: 25.5-36.9%); and South America demonstrated the highest proportion at 38.8% (95% CI: 34.4-43.3%). Meta-regression analyses identified significant associations between MetS prevalence and key clinical variables, including waist circumference (WC) (β = 0.01; P = 0.01), body mass index (BMI) (β = 0.04; P < 0.01), triglycerides (TG) (β < 0.01; P = 0.04), and fasting blood glucose (FBG) (β < 0.01; P < 0.01), with high-density lipoprotein (HDL) levels showing an inverse association (β = -0.01; P < 0.01). Among various diagnostic criteria, the highest prevalence estimates were obtained with the National Cholesterol Education Program and International Diabetes Federation (NCEP/IDF) criteria (39.2%; 95% CI: 30.6-48.1), followed by the Joint Consensus (JC) criteria (37.2%; 95% CI: 28.0-46.9) and the 2004 revision of the National Cholesterol Education Program ATP III (NCEP 2004) criteria (35.4%; 95% CI: 29.0-42.0).</p><p><strong>Conclusion: </strong>The substantial prevalence of MetS among RA patients underscores the need for a proactive, integrated approach to cardiovascular risk management. Clinicians should consider routine screening for MetS components-such as central obesity, hypertension, dysglycemia, and dyslipidemia-particularly given the significant associations with WC, BMI, TG, and FBG levels.</p><p><strong>Clinical trial number: </strong>Not applica","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"116"},"PeriodicalIF":2.5,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12513099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145273741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-03DOI: 10.1186/s41927-025-00570-3
Longhua Fu, Meng Ge, Fangbing Zhu, Weibin Du, Zhenfei Xiong, Zhengcong Ye, Huahui Hu, Shenghu Hong
{"title":"Rheumatoid arthritis continues to increase in low-middle SDI and low SDI quintiles based on GBD 1990-2021.","authors":"Longhua Fu, Meng Ge, Fangbing Zhu, Weibin Du, Zhenfei Xiong, Zhengcong Ye, Huahui Hu, Shenghu Hong","doi":"10.1186/s41927-025-00570-3","DOIUrl":"10.1186/s41927-025-00570-3","url":null,"abstract":"","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"114"},"PeriodicalIF":2.5,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495846/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145224896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-03DOI: 10.1186/s41927-025-00569-w
Khaled Aldhuaina, Khawla Alghanim
{"title":"Efficacy and safety of avacopan in the treatment of ANCA-associated vasculitis: a systematic review and meta-analysis.","authors":"Khaled Aldhuaina, Khawla Alghanim","doi":"10.1186/s41927-025-00569-w","DOIUrl":"10.1186/s41927-025-00569-w","url":null,"abstract":"","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"115"},"PeriodicalIF":2.5,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145224941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-02DOI: 10.1186/s41927-025-00561-4
Florentia Kitas, Carolyn Greig, Jet Veldhuijzen van Zanten, Sally A M Fenton
Background: Sedentary behaviour (SB) is receiving increasing attention as a potential target for behavioural change interventions in people with Rheumatoid Arthritis (RA), to improve RA outcomes. The primary aim of this review was to describe the design and content of existing SB interventions in RA with a focus on the use of digital technology and Behaviour Change Techniques (BCTs). Secondary aims were to understand how SB is conceptualised in intervention studies, and report data on participants' perceptions of acceptable and/or engaging components, adherence, and intervention efficacy.
Methods: Six databases (Cochrane Library, Medline, PubMed, Excerpta Medica database (EMBASE), APA Psychnet and OVID Journals) were searched from inception-October 2024. Inclusion criteria required publications to report on a behaviour change intervention targeting SB (directly or indirectly) in people with RA, and assessed SB as an outcome. Interventions in people with Osteoarthritis (OA) were also included, for a broader understanding.
Results: Initial searches returned 1,530 articles. Following screening, 30 articles underwent full text review, and 8 articles reporting interventions in RA (3/8, 38%) and OA (5/8, 62%) met the inclusion criteria. Only one RA intervention was specifically focused on SB, with the remaining seven targeting physical activity (PA), self-management or health outcomes. A hybrid delivery approach (in-person + digital, i.e., text messages and/or emails, apps, websites) was adopted by six interventions. Reporting of BCTs was inconsistent, but 'Goals and Planning' and 'Feedback and Monitoring' were used by all interventions. There was heterogeneity in the definition of SB and limited data on acceptable/engaging components. However, most studies reported measures of intervention/study adherence, and two interventions demonstrated preliminary evidence of intervention effects on SB and/or patient/clinician important outcomes.
Conclusion: This review highlights a focus on hybrid delivery of interventions targeting SB in people with RA and/or OA, offering opportunities for personalisation and saving personal and healthcare resources. More standardised approaches to reporting intervention design (e.g. employing established definitions and validated measures of SB) and content (e.g. BCTs), alongside evaluation of intervention acceptability/engagement is required. This is critical to further understanding of interventions likely to be accepted by people with RA, and thus more likely effective at reducing SB and improving RA outcomes.
{"title":"Sedentary behaviour interventions in rheumatoid arthritis and osteoarthritis: a systematic scoping review of intervention content, perceived acceptability and efficacy.","authors":"Florentia Kitas, Carolyn Greig, Jet Veldhuijzen van Zanten, Sally A M Fenton","doi":"10.1186/s41927-025-00561-4","DOIUrl":"10.1186/s41927-025-00561-4","url":null,"abstract":"<p><strong>Background: </strong>Sedentary behaviour (SB) is receiving increasing attention as a potential target for behavioural change interventions in people with Rheumatoid Arthritis (RA), to improve RA outcomes. The primary aim of this review was to describe the design and content of existing SB interventions in RA with a focus on the use of digital technology and Behaviour Change Techniques (BCTs). Secondary aims were to understand how SB is conceptualised in intervention studies, and report data on participants' perceptions of acceptable and/or engaging components, adherence, and intervention efficacy.</p><p><strong>Methods: </strong>Six databases (Cochrane Library, Medline, PubMed, Excerpta Medica database (EMBASE), APA Psychnet and OVID Journals) were searched from inception-October 2024. Inclusion criteria required publications to report on a behaviour change intervention targeting SB (directly or indirectly) in people with RA, and assessed SB as an outcome. Interventions in people with Osteoarthritis (OA) were also included, for a broader understanding.</p><p><strong>Results: </strong>Initial searches returned 1,530 articles. Following screening, 30 articles underwent full text review, and 8 articles reporting interventions in RA (3/8, 38%) and OA (5/8, 62%) met the inclusion criteria. Only one RA intervention was specifically focused on SB, with the remaining seven targeting physical activity (PA), self-management or health outcomes. A hybrid delivery approach (in-person + digital, i.e., text messages and/or emails, apps, websites) was adopted by six interventions. Reporting of BCTs was inconsistent, but 'Goals and Planning' and 'Feedback and Monitoring' were used by all interventions. There was heterogeneity in the definition of SB and limited data on acceptable/engaging components. However, most studies reported measures of intervention/study adherence, and two interventions demonstrated preliminary evidence of intervention effects on SB and/or patient/clinician important outcomes.</p><p><strong>Conclusion: </strong>This review highlights a focus on hybrid delivery of interventions targeting SB in people with RA and/or OA, offering opportunities for personalisation and saving personal and healthcare resources. More standardised approaches to reporting intervention design (e.g. employing established definitions and validated measures of SB) and content (e.g. BCTs), alongside evaluation of intervention acceptability/engagement is required. This is critical to further understanding of interventions likely to be accepted by people with RA, and thus more likely effective at reducing SB and improving RA outcomes.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"113"},"PeriodicalIF":2.5,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12492876/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145211573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1186/s41927-025-00528-5
Aaron Teel, Adrian Grebowicz, Yuliya Lytvyn, Stephanie Garner, C Thomas Appleton, Alexandra P Saltman, Nader Khalidi, Mats Junek, Faiza Khokhar
Background: Immune checkpoint inhibitors (ICIs) have been associated with immune-related adverse events (irAEs), including ICI associated vasculitis (ICI-vasculitis) and ICI associated PMR (ICI-polymyalgia rheumatica (PMR)-like syndromes). We sought to describe the characteristics of ICI-vasculitis and ICI-PMR in individuals treated with ICIs through a systematic review and local case series.
Methods: We searched MEDLINE and Embase from inception to July 2023 for cases of ICI-vasculitis and ICI-PMR in ICI-treated individuals. Our series included cases obtained from clinicians at the Universities of Toronto, McMaster, and Western in Ontario, Canada.
Results: One hundred and forty-four patients were identified: 130 from the systematic review in 76 articles and 14 from our case series. This included 73 patients with ICI-vasculitis (14 large vessel, 7 ANCA-associated, 52 other) and 71 with ICI-PMR. Ninety-five per cent of patients were treated with glucocorticoids and 17% received disease-modifying antirheumatic drugs (DMARDs). Among 4 individuals with vasculitis who continued the ICI, two remitted. Of five who paused and restarted ICIs, one experienced a recurrence. Among four individuals with vasculitis who continued ICIs, two remitted. All 11 ICI-PMR cases that continued ICIs remitted; among 3 patients who paused and restarted two did not relapse and one had a relapse that improved with an increase in their dose of prednisone.
Conclusion: ICI-vasculitis and ICI-PMR are underrecognized complications of ICIs. Glucocorticoids are effective for ICI-vasculitis and ICI-PMR. It is unclear if ICIs can be safely continued or restarted after remission of ICI-vasculitis or ICI-PMR. Limited data suggests ICIs may be resumed in individuals with non-severe ICI-vasculitis or ICI-PMR.
{"title":"Immune checkpoint inhibitor associated vasculitis and polymyalgia rheumatica: a case series and systematic review.","authors":"Aaron Teel, Adrian Grebowicz, Yuliya Lytvyn, Stephanie Garner, C Thomas Appleton, Alexandra P Saltman, Nader Khalidi, Mats Junek, Faiza Khokhar","doi":"10.1186/s41927-025-00528-5","DOIUrl":"10.1186/s41927-025-00528-5","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors (ICIs) have been associated with immune-related adverse events (irAEs), including ICI associated vasculitis (ICI-vasculitis) and ICI associated PMR (ICI-polymyalgia rheumatica (PMR)-like syndromes). We sought to describe the characteristics of ICI-vasculitis and ICI-PMR in individuals treated with ICIs through a systematic review and local case series.</p><p><strong>Methods: </strong>We searched MEDLINE and Embase from inception to July 2023 for cases of ICI-vasculitis and ICI-PMR in ICI-treated individuals. Our series included cases obtained from clinicians at the Universities of Toronto, McMaster, and Western in Ontario, Canada.</p><p><strong>Results: </strong>One hundred and forty-four patients were identified: 130 from the systematic review in 76 articles and 14 from our case series. This included 73 patients with ICI-vasculitis (14 large vessel, 7 ANCA-associated, 52 other) and 71 with ICI-PMR. Ninety-five per cent of patients were treated with glucocorticoids and 17% received disease-modifying antirheumatic drugs (DMARDs). Among 4 individuals with vasculitis who continued the ICI, two remitted. Of five who paused and restarted ICIs, one experienced a recurrence. Among four individuals with vasculitis who continued ICIs, two remitted. All 11 ICI-PMR cases that continued ICIs remitted; among 3 patients who paused and restarted two did not relapse and one had a relapse that improved with an increase in their dose of prednisone.</p><p><strong>Conclusion: </strong>ICI-vasculitis and ICI-PMR are underrecognized complications of ICIs. Glucocorticoids are effective for ICI-vasculitis and ICI-PMR. It is unclear if ICIs can be safely continued or restarted after remission of ICI-vasculitis or ICI-PMR. Limited data suggests ICIs may be resumed in individuals with non-severe ICI-vasculitis or ICI-PMR.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"111"},"PeriodicalIF":2.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12487409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1186/s41927-025-00568-x
Samar Al Emadi, Eman Satti, Priyanka Cackamvalli, Nawal Hadwan
Background: Chronic inflammatory arthritis, including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and spondyloarthritis (SpA), poses unique challenges during pregnancy due to potential maternal and fetal complications. This study aimed to compare pregnancy outcomes among women with these conditions in Qatar.
Methods: A retrospective cohort study was conducted at Hamad General Hospital from 2016 to 2022. Data on sociodemographic characteristics, disease features (e.g., disease duration, serological markers), treatments, and pregnancy outcomes were extracted from electronic medical records. Pregnancy outcomes included miscarriage, live birth, and intrauterine fetal demise (IUFD); delivery data such as term, weeks of gestation, and mode of delivery; and neonatal data including birth weight, low birth weight (LBW), congenital anomalies, and NICU admissions. Multivariable logistic regression was used to identify associations between disease subtype, medication use, and pregnancy outcomes.
Results: A total of 189 pregnant women were included (RA = 131, SpA = 29, and PsA = 29). Pregnancy outcomes were compared across the three patient groups: SpA was associated with the highest live birth rate (89.7%), while PsA had the highest rate of NICU admissions (13.8%) and lowest preterm birth rate (6.9%). Intrauterine growth restriction (IUGR) occurred only in RA (31%). Multivariable analyses showed that SpA was linked to significantly higher odds of live birth and lower risks of miscarriage, peripartum complications, and low birth weight compared to RA. PsA was associated with a reduced risk of preterm birth. Advanced maternal age increases the risk of any complication taken together. Sulfasalazine use was associated with lower miscarriage risk and higher likelihood of live birth, but also increased NICU admissions, as did anti-TNF therapy. Hydroxychloroquine use was associated with a protective effect against NICU admissions and low birth weight.
Conclusion: Pregnancy outcomes vary significantly across chronic inflammatory arthritis subtypes. Our findings underscore the need for individualized, multidisciplinary care and further prospective studies to guide clinical management.
{"title":"Maternal and neonatal outcomes in pregnancies with rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: a comparative study.","authors":"Samar Al Emadi, Eman Satti, Priyanka Cackamvalli, Nawal Hadwan","doi":"10.1186/s41927-025-00568-x","DOIUrl":"10.1186/s41927-025-00568-x","url":null,"abstract":"<p><strong>Background: </strong>Chronic inflammatory arthritis, including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and spondyloarthritis (SpA), poses unique challenges during pregnancy due to potential maternal and fetal complications. This study aimed to compare pregnancy outcomes among women with these conditions in Qatar.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted at Hamad General Hospital from 2016 to 2022. Data on sociodemographic characteristics, disease features (e.g., disease duration, serological markers), treatments, and pregnancy outcomes were extracted from electronic medical records. Pregnancy outcomes included miscarriage, live birth, and intrauterine fetal demise (IUFD); delivery data such as term, weeks of gestation, and mode of delivery; and neonatal data including birth weight, low birth weight (LBW), congenital anomalies, and NICU admissions. Multivariable logistic regression was used to identify associations between disease subtype, medication use, and pregnancy outcomes.</p><p><strong>Results: </strong>A total of 189 pregnant women were included (RA = 131, SpA = 29, and PsA = 29). Pregnancy outcomes were compared across the three patient groups: SpA was associated with the highest live birth rate (89.7%), while PsA had the highest rate of NICU admissions (13.8%) and lowest preterm birth rate (6.9%). Intrauterine growth restriction (IUGR) occurred only in RA (31%). Multivariable analyses showed that SpA was linked to significantly higher odds of live birth and lower risks of miscarriage, peripartum complications, and low birth weight compared to RA. PsA was associated with a reduced risk of preterm birth. Advanced maternal age increases the risk of any complication taken together. Sulfasalazine use was associated with lower miscarriage risk and higher likelihood of live birth, but also increased NICU admissions, as did anti-TNF therapy. Hydroxychloroquine use was associated with a protective effect against NICU admissions and low birth weight.</p><p><strong>Conclusion: </strong>Pregnancy outcomes vary significantly across chronic inflammatory arthritis subtypes. Our findings underscore the need for individualized, multidisciplinary care and further prospective studies to guide clinical management.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"112"},"PeriodicalIF":2.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12486653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-30DOI: 10.1186/s41927-025-00557-0
Girish Pattappa, Niclas G Karlsson, Bibiane Steinecker-Frohnwieser, Ali Mobasheri, Eiva Bernotiene, Frank Zaucke, Gundula Roesch, Ilona Uzieliene, Ingrid Meulenbelt, Jaqueline Lourdes Rios, Maria Kazakova, Marie-Astrid Boutet, Mona Dvir-Ginzberg, Valerija Groma, Zsuzsa Jenei-Lanzl, Yves Henrotin, Zhen Li, Sylvia Nürnberger, Cecilia Aulin
{"title":"Towards stratification in osteoarthritis: a review of the scientific terminology used in published basic research.","authors":"Girish Pattappa, Niclas G Karlsson, Bibiane Steinecker-Frohnwieser, Ali Mobasheri, Eiva Bernotiene, Frank Zaucke, Gundula Roesch, Ilona Uzieliene, Ingrid Meulenbelt, Jaqueline Lourdes Rios, Maria Kazakova, Marie-Astrid Boutet, Mona Dvir-Ginzberg, Valerija Groma, Zsuzsa Jenei-Lanzl, Yves Henrotin, Zhen Li, Sylvia Nürnberger, Cecilia Aulin","doi":"10.1186/s41927-025-00557-0","DOIUrl":"10.1186/s41927-025-00557-0","url":null,"abstract":"","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"109"},"PeriodicalIF":2.5,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12487489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145198431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-30DOI: 10.1186/s41927-025-00564-1
Roma Desai, John B Miller
{"title":"Non-radiographic axial spondyloarthritis developing after Lyme arthritis: a case report and review.","authors":"Roma Desai, John B Miller","doi":"10.1186/s41927-025-00564-1","DOIUrl":"10.1186/s41927-025-00564-1","url":null,"abstract":"","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"110"},"PeriodicalIF":2.5,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12487456/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145198367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号